US Broker Ratings

Kiniksa Pharmaceuticals, Ltd. (KNSA)

⚠️ No article content returned.

..

Ocular Therapeutix, Inc. (OCUL) Stock Analysis: Eyeing a 48.32% Upside with Strong Buy Consensus

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is capturing the attention of investors with its promising advancements in the biotechnology sector. As a company specializing in biopharmaceutical solutions for retinal diseases and..

Janux Therapeutics, Inc. (JANX) Stock Analysis: A 223% Potential Upside Captures Investor Attention

Janux Therapeutics, Inc. (NASDAQ: JANX), a clinical-stage biopharmaceutical company, is making waves in the biotechnology sector with its innovative immunotherapy platforms. Despite a recent slight dip in its stock price..

Schrodinger, Inc. (SDGR) Investor Outlook: Exploring a Potential 39.45% Upside

Investors eyeing opportunities in the healthcare sector might find Schrödinger, Inc. (NASDAQ: SDGR) an intriguing prospect, especially given its forecasted potential upside of 39.45%. Specializing in the dynamic field of..

Clover Health Investments (CLOV) Stock Analysis: A Healthcare Challenger with 56% Potential Upside

Clover Health Investments, Corp. (NASDAQ: CLOV) stands out in the healthcare sector with its innovative approach to Medicare Advantage plans, leveraging its proprietary software, Clover Assistant, to enhance patient care...

MiMedx Group, Inc. (MDXG) Stock Analysis: Exploring a 76.73% Potential Upside in the Biotechnology Sector

MiMedx Group, Inc. (NASDAQ: MDXG), a key player in the biotechnology sector, offers a promising investment opportunity with its innovative approach to healthcare solutions. Headquartered in Marietta, Georgia, MiMedx develops..

Arrowhead Pharmaceuticals (ARWR) Stock Analysis: Exploring a 171.60% Potential Upside

For investors intrigued by the potential of biotechnology stocks, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) presents an intriguing opportunity. With a robust pipeline of products in clinical trials and a compelling..

Celldex Therapeutics (CLDX) Stock Analysis: Exploring a Potential 165.96% Upside in Biotech

Celldex Therapeutics, Inc. (NASDAQ: CLDX), a dynamic player in the biotechnology sector, has captured the attention of investors with its impressive growth potential and innovative approach to treating severe inflammatory..

Surgery Partners, Inc. (SGRY) Stock Analysis: Uncovering a 39.77% Potential Upside Amid Healthcare Growth

Surgery Partners, Inc. (NASDAQ: SGRY), a prominent player in the healthcare sector, has been catching the eye of investors with its robust network of surgical facilities across the United States...

Select Medical Holdings Corp (SEM) Stock Analysis: A 44.88% Potential Upside Worth Watching

Select Medical Holdings Corporation (NYSE: SEM) is a key player in the healthcare sector, operating a diverse network of critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics across..

National HealthCare Corporation (NHC) Stock Analysis: A Deeper Look into Its 25.7% Revenue Growth and Dividend Yield

National HealthCare Corporation (NYSE: NHC), a key player in the healthcare sector, offers a diverse range of services focusing on skilled nursing facilities, assisted living, homecare, and hospice services. Based..

Ardent Health, Inc. (ARDT) Stock Analysis: Potential Upside of Nearly 90% Awaits Investors

Ardent Health, Inc. (ARDT), a key player in the healthcare sector, is drawing investor attention with a compelling potential upside of 89.83%. As a company operating a vast network of..

Warby Parker Inc. (WRBY) Stock Analysis: Evaluating a Healthcare Retail Innovator with 11.9% Revenue Growth

Warby Parker Inc. (NYSE: WRBY) stands out as an intriguing player in the healthcare sector, nestled within the medical instruments and supplies industry. Known for its innovative approach to eyewear..

BGM Group Ltd. (BGM) Stock Analysis: Navigating Challenges in the Healthcare Sector

BGM Group Ltd. (BGM), a prominent player in China’s healthcare sector, is currently navigating a challenging financial landscape. With a market capitalization of $2.01 billion, the company operates within the..

Novavax, Inc. (NVAX) Stock Analysis: Exploring a Potential 82.50% Upside in the Biotech Sector

Novavax, Inc. (NVAX), a prominent player in the biotechnology industry, has captured investor attention with its innovative vaccine technologies and significant potential upside. Headquartered in Gaithersburg, Maryland, Novavax specializes in..

Apogee Therapeutics, Inc. (APGE) Stock Analysis: Exploring a Potential Upside of 143.95% in the Biotech Arena

Apogee Therapeutics, Inc. (NASDAQ: APGE), a burgeoning entity in the biotechnology sector, has caught the attention of investors with its promising prospects in the treatment of inflammatory and immunological diseases...

Adaptive Biotechnologies (ADPT) Stock Analysis: A Promising Biotech Play with 14.45% Upside Potential

Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a key player in the biotechnology sector, is attracting attention from investors with its innovative approach to diagnosing and treating diseases through its immune medicine..

Omnicell, Inc. (OMCL) Stock Analysis: A 51% Upside Potential in Healthcare Tech

Omnicell, Inc. (NASDAQ: OMCL) stands as a noteworthy player in the healthcare technology sector, specializing in medication management solutions and adherence tools. With a market capitalization of $1.36 billion, this..

Pacira BioSciences, Inc. (PCRX) Stock Analysis: Exploring a 39.68% Potential Upside

Investors with a focus on the healthcare sector may find Pacira BioSciences, Inc. (NASDAQ: PCRX) an intriguing prospect given its potential upside of nearly 40%. With a market capitalization of..

HUTCHMED (China) Limited (HCM) Stock Analysis: Discovering a 35% Upside Potential in the Healthcare Sector

HUTCHMED (China) Limited (HCM), a prominent player in the healthcare sector, is capturing investor attention with its promising 35.03% potential upside, according to current analyst targets. Headquartered in Hong Kong,..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds